12/07/2022
London, UK, 12 July 2022: Ixaka Ltd, an integrated cell and gene therapy company focused on boosting the natural power…
Read More
27/06/2022
REX-001 is an autologous multi-cell therapy (MCT) in development for the treatment of chronic limb-threatening ischemia (CLTI) in patients with…
Read More
21/03/2022
London, UK, 21 March 2022– Ixaka Ltd, an integrated cell and gene therapy company, today announces an expansion of its…
Read More
08/03/2022
CELTIC-19 – Ixaka’s targeted nanoparticle for CD19 haematological malignancies – has been granted Advanced Therapy Medicinal Product (ATMP) classification by…
Read More
10/02/2022
Nick Robbins-Cherry, ex-Midatech, joins as CFO George O’Rourke, joins as VP & GM Ixaka France, from Novartis Gene Therapy London,…
Read More
08/09/2021
The positive interim analysis of the efficacy and safety results from the first 30% of enrolled patients evaluated 12 months…
Read More
31/08/2021
CSO, Cecile Bauche, also chairing panel discussion on optimising animal models for cell therapy Five posters covering the application of…
Read More
02/08/2021
London, UK, 2 August 2021: Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of…
Read More
29/06/2021
Ixaka Ltd and SomaLogic today announce a research collaboration to support the development of aptamer-based bispecific therapeutics. The collaboration will…
Read More
19/04/2021
Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease,…
Read More
30/03/2021
Ixaka Ltd and Leiden University Medical Center (LUMC) today announce a research collaboration to expand understanding of Ixaka’s lead multi-cell…
Read More
08/02/2021
Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease,…
Read More
18/01/2021
London, UK, 18 January 2021: Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of…
Read More
07/12/2020
Rexgenero, a regenerative medicine company developing advanced cell therapies to treat chronic limb-threatening ischemia (CLTI), today announces the appointment of…
Read More
26/10/2020
REX-001 is an autologous cell-based product intended to treat critical limb-threatening ischaemia in diabetic patients Independent Data Monitoring Committee recommended…
Read More
02/07/2020
London, UK, 2 July 2020: Rexgenero, a regenerative medicine company developing advanced cell therapies to treat chronic limb-threatening ischaemia (CLI), today…
Read More
22/06/2020
Rexgenero, a regenerative medicine company developing advanced cell therapies to treat chronic limb-threatening ischaemia (CLI), today announces the acquisition of…
Read More
12/02/2020
Rexgenero, a regenerative medicine company developing advanced cell therapies to treat chronic limb-threatening ischaemia (CLI), today announces that Dr Huw…
Read More
10/02/2020
Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischemia (CLI), today announces…
Read More
04/12/2019
Phase III SALAMANDER Trials of Rexgenero’s REX-001 Open and Recruiting Patients at the University Hospital of Wales in Cardiff The…
Read More
19/10/2019
Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischemia (CLI), announces today…
Read More
11/09/2019
Rexgenero, a clinical-stage regenerative medicine company pioneering the development of advanced cell-based therapies, has been shortlisted as a finalist for…
Read More
21/08/2019
Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischaemia (CLI), welcomes the…
Read More
29/05/2019
Phase III SALAMANDER Trial of Rexgenero’s REX-001 Open and Recruiting The first diabetic patient in the Czech Republic with a…
Read More
28/05/2019
Enables new sites to participate in the European Phase III SALAMANDER trials Rexgenero, a regenerative medicine company developing advanced cell-based…
Read More
24/04/2019
At the Alliance for Regenerative Medicine’s Cell and Gene Therapy ‘Meeting on the Med’ in Barcelona Rexgenero, a regenerative medicine…
Read More
Rexgenero’s Lead Product REX-001 Selected for the EUnetHTA Prioritisation List for Joint Assessments
07/01/2019
The Prioritisation list consists of just 14 medicinal products that have been identified as being of significant interest by national…
Read More
30/01/2018
REX-001 is a novel cell therapy for the treatment of Critical Limb Ischemia (CLI), a disease which affects an estimated…
Read More
25/01/2018
London, UK, 25th January 2018: Rexgenero Ltd, a clinical-stage regenerative medicine company developing advanced cell-based therapies with a focus on…
Read More
23/01/2018
London, UK, 23rd January 2018: Rexgenero Ltd, a clinical-stage regenerative medicine company developing advanced cell-based therapeutics with a focus on…
Read More
13/11/2017
London, UK, 13 November 2017: Rexgenero Ltd, a clinical-stage regenerative medicine company developing advanced cell-based therapeutics with a focus on…
Read More
05/01/2017
Rexgenero Announces Formation of Scientific Advisory Board and Appoints Leading Experts in Cell Therapy, Cardiovascular Diseases and Wound Healing …
Read More
13/10/2016
London, UK. Rexgenero received a Follow-up Scientific Advice letter from the Committee for Medicinal Products for Human Use (CHMP) of…
Read More
03/10/2016
London, UK. Rexgenero Ltd appoints Karen Reitsma as Vice President, Clinical and Regulatory Development. Karen is an expert in the…
Read More
14/04/2016
Promising Innovative Medicine Designation (PIM) issued from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Rexmyelocel-T for the…
Read More
04/01/2016
London, UK. Rexgenero Ltd appoints Liesbeth de Jong as Vice President, Manufacturing and R&D. Liesbeth brings extensive experience in cellular…
Read More
25/11/2015
Rexgenero receives scientific advice from the MHRA (the UK pharmaceutical regulator) regarding quality and clinical aspects of Rexgenero planned phase…
Read More
08/10/2015
Rexgenero receives scientific advice from the Paul Ehlich Institute (the German pharmaceutical regulator) regarding quality and clinical aspects of Rexgenero…
Read More
24/07/2015
London UK. Rexgenero receives notification from The Committee for Advanced Therapies (CAT) of the European Medicines Agency (EMA) that EMA…
Read More
05/06/2015
Opening of Rexgenero Biosciences analytical laboratory in the Isla Cartuja in Seville, Spain.
Read More
07/05/2015
Seville, Spain. Rexgenero incorporates Spanish subsidiary Rexgenero S.L. to oversee research, development and manufacturing operations of the company.
Read More
30/03/2015
London, UK. Rexgenero Ltd appoints Edwin Wagena as Chief Operating Officer with responsibility for clinical development and manufacturing. Edwin has…
Read More
30/03/2015
Seville, Spain. Rexgenero incorporates Spanish subsidiary Rexgenero S.L. to oversee research, development and manufacturing operations of the company.
Read More
27/03/2015
Rexgenero Ltd enters into exclusive licence agreement with Fundación Progreso y Salud (FPS) and the Servicio Andaluz de Salud (SAS)…
Read More